MS NOW reported that nearly a dozen drugmakers are slated to sign voluntary deals with President Donald Trump to sell their medications for less. ^[1] U.S. President Donald Trump announced drug-pricing deals with more than 20 pharmaceutical companies to reduce prescription costs, which are often nearly three times higher than those paid by patients in other developed countries. ^[2] Bloomberg reported that the expected deals require drugmakers to provide discounts on outpatient drugs to state Medicaid programs so prices align with foreign countries. ^[3] President Trump is scheduled to make an announcement about healthcare affordability at 3:00 p.m. ET on Monday at the White House. ^[4] The Trump administration has reached drug pricing deals with 17 pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk, as part of its 'most favored nation' policy. ^[5] A second wave announced in late August added agreements with nine companies, including smaller biotechs, offering drugs to state Medicaid programs at most-favoured-nation prices. ^[6] Eli Lilly agreed in November to offer Medicare beneficiaries its obesity medicines Zepbound and orforglipron, branded as Foundayo, at no more than $50 per month, with additional discounts for self-pay patients through LillyDirect. ^[7] The first wave of deals included 17 major drugmakers starting last year, featuring commitments to most-favoured-nation pricing, sales through the TrumpRx.gov platform, and U.S. investment pledges in exchange for tariff relief. ^[8]